BRL Medicine Reports Positive Results for TyU19 in Refractory SLE Trial
Shanghai-based BRL Medicine Inc. announced positive results from an investigator-initiated trial (ITT) evaluating its allogeneic...
BRL Medicine
BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline
On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan...
Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....
BRL Medicine Raises RMB 200M in Series B Financing for CGT Development
BRL Medicine Inc., a cell and gene therapy (CGT) developer based in Shanghai, has reportedly...
BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia
Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...